This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Generated small-molecule compounds with IC50 values in the single-digit μM range against CTLA-4.
Why it matters
Targeting protein-protein interactions is crucial for developing effective therapies. This new strategy could streamline the design of small-molecule drugs, making them more accessible.
How the study worked
The study utilized ribosomal display to identify inhibitory cyclic peptides, followed by conversion to small molecules using PepMetics® scaffolds.
What this study cannot tell us
The study primarily focuses on in vitro results, which may not directly translate to in vivo efficacy in humans.
Read the original research
Rational Strategy for Designing Peptidomimetic Small Molecules Based on Cyclic Peptides Targeting Protein-Protein Interaction between CTLA-4 and B7-1.
Pharmaceuticals (Basel, Switzerland), 15(12)
Citation
Tsuihiji, Kumiko; Honda, Eiji; Kojoh, Kanehisa; Katoh, Shizue; Taguri, Tomonori; Yoshimori, Atsushi; Takashima, Hajime. (2022). Rational Strategy for Designing Peptidomimetic Small Molecules Based on Cyclic Peptides Targeting Protein-Protein Interaction between CTLA-4 and B7-1.. Pharmaceuticals (Basel, Switzerland), 15(12). https://doi.org/10.3390/ph15121506